In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections
- PMID: 18087627
In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections
Abstract
Background and purpose: Isepamicin is a newly introduced aminoglycoside in Taiwan. Since in vitro data for isepamicin against nosocomial Gram-negative bloodstream infection from Taiwan are limited, we compared the activity of isepamicin, amikacin, gentamicin and tobramycin against nosocomial Gram-negative blood isolates.
Methods: A total of 247 non-duplicate nosocomial blood isolates of Gram-negative bacteria collected between January 2003 and December 2003 in a major teaching hospital in Taiwan were tested for their in vitro susceptibilities to gentamicin, tobramycin, amikacin, and isepamicin using the agar dilution method. The isolates included Escherichia coli (31 isolates), Klebsiella pneumoniae (31), Enterobacter cloacae (30), Serratia marcescens (31), Morganella morganii (21), Citrobacter freundii (10), Pseudomonas aeruginosa (31), Acinetobacter baumannii (31), and Stenotrophomonas maltophilia (31).
Results: Overall, isepamicin had high antibacterial activity against the tested Gram-negative bacteria. For the 154 Enterobacteriaceae isolates, isepamicin had the lowest minimum concentration inhibiting 90% of isolates (MIC90) among the tested drugs, while its resistance rate (3.9%) was equal to that of amikacin (3.9%) and lower than those of tobramycin (18.2%) and gentamicin (21.4%). For the 93 of non-fermentative Gram-negative bacilli isolates, isepamicin had the lowest MIC90, and a resistance rate (23.7%) lower than those of amikacin (27.9%), tobramycin (38.7%) and gentamicin (40.9%).
Conclusions: The in vitro activity of isepamicin against Gram-negative bacteria isolates was equal or similar to amikacin and superior to other tested aminoglycosides. In view of its potential for less nephrotoxicity and ototoxicity than other aminoglycosides, isepamicin is a drug of choice for the empirical treatment of nosocomial infections caused by Gram-negative bacteria.
Similar articles
-
In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.J Microbiol Immunol Infect. 2016 Dec;49(6):918-923. doi: 10.1016/j.jmii.2015.07.010. Epub 2015 Aug 14. J Microbiol Immunol Infect. 2016. PMID: 26364729
-
[Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].Zhonghua Yi Xue Za Zhi. 2007 Oct 23;87(39):2753-8. Zhonghua Yi Xue Za Zhi. 2007. PMID: 18167265 Chinese.
-
In vitro susceptibility of nosocomial isolates against a new aminoglycoside isepamicin.Indian J Med Res. 2001 Feb;113:60-2. Indian J Med Res. 2001. PMID: 21910285
-
Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.J Chemother. 1995 Jun;7 Suppl 2:7-16. J Chemother. 1995. PMID: 8622113 Review.
-
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73. doi: 10.1586/eri.12.25. Expert Rev Anti Infect Ther. 2012. PMID: 22512755 Review.
Cited by
-
Antimicrobial susceptibility of non-fermenting Gram-negative isolates to isepamicin in a region with high antibiotic resistance.Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3191-8. doi: 10.1007/s10096-012-1684-9. Epub 2012 Jul 1. Eur J Clin Microbiol Infect Dis. 2012. PMID: 22752194
-
Bacteriological profile of wound infections and antimicrobial resistance in selected gram-negative bacteria.Afr Health Sci. 2022 Dec;22(4):576-586. doi: 10.4314/ahs.v22i4.63. Afr Health Sci. 2022. PMID: 37092080 Free PMC article.
-
High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy.PLoS One. 2010 Nov 30;5(11):e14133. doi: 10.1371/journal.pone.0014133. PLoS One. 2010. PMID: 21152436 Free PMC article.
-
Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.PLoS One. 2011 Feb 17;6(2):e17224. doi: 10.1371/journal.pone.0017224. PLoS One. 2011. PMID: 21359143 Free PMC article.
-
In-vitro Activity of Isepamicin against Gram-negative Bacteria in Comparison to Other Aminoglycosides Routinely used at a Teaching Hospital in Northern India.J Lab Physicians. 2023 Mar 22;15(3):419-424. doi: 10.1055/s-0043-1761928. eCollection 2023 Sep. J Lab Physicians. 2023. PMID: 37564217 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical